Tokyo Tape
Sign in
← Noile-Immune Biotech

Annual report

4893.TEDINET S100XSP4
Period2025-01-01 → 2025-12-31
Filed2026-03-23
StandardJapan GAAP
ConsolidatedNo
Data checks11 of 11 passed
Key figures · 77
MetricValuePeriodScopeSource row
Revenue¥5m2025-01-01 → 2025-12-31StandaloneOperating revenues (key data)
Revenue¥8m2024-01-01 → 2024-12-31StandaloneOperating revenues (key data)
Revenue¥317m2023-01-01 → 2023-12-31vStandaloneOperating revenues (key data)
Revenue¥626m2022-01-01 → 2022-12-31dStandaloneOperating revenues (key data)
Revenue¥101m2021-01-01 → 2021-12-31dStandaloneOperating revenues (key data)
Operating income−¥797m2025-01-01 → 2025-12-31StandaloneOperating income
Operating income−¥1.1bn2024-01-01 → 2024-12-31StandaloneOperating income
Ordinary income−¥791m2025-01-01 → 2025-12-31StandaloneOrdinary income
Ordinary income−¥962m2024-01-01 → 2024-12-31StandaloneOrdinary income
Ordinary income−¥1.1bn2023-01-01 → 2023-12-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥384m2022-01-01 → 2022-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥793m2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥791m2025-01-01 → 2025-12-31StandaloneIncome before income taxes
Profit before tax−¥962m2024-01-01 → 2024-12-31StandaloneIncome before income taxes
Net income−¥794m2025-01-01 → 2025-12-31StandaloneProfit loss
Net income−¥964m2024-01-01 → 2024-12-31StandaloneProfit loss
Net income−¥1.1bn2023-01-01 → 2023-12-31vStandaloneNet income loss (5-year summary)
Net income−¥387m2022-01-01 → 2022-12-31dStandaloneNet income loss (5-year summary)
Net income−¥795m2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Total assets¥4.0bnat 2025-12-31StandaloneAssets
Total assets¥4.8bnat 2024-12-31StandaloneAssets
Total assets¥5.8bnat 2023-12-31vStandaloneTotal assets (5-year summary)
Total assets¥4.6bnat 2022-12-31dStandaloneTotal assets (5-year summary)
Total assets¥4.3bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥80mat 2025-12-31StandaloneLiabilities
Total liabilities¥75mat 2024-12-31StandaloneLiabilities
Net assets / equity¥3.9bnat 2025-12-31StandaloneNet assets
Net assets / equity¥4.7bnat 2024-12-31StandaloneNet assets
Net assets / equity¥5.7bnat 2023-12-31vStandaloneNet assets
Net assets / equity¥4.3bnat 2022-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥4.2bnat 2021-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥3.9bnat 2025-12-31StandaloneCash and deposits
Cash and deposits¥4.7bnat 2024-12-31StandaloneCash and deposits
Cash & equivalents¥3.9bnat 2025-12-31StandaloneCash and cash equivalents
Cash & equivalents¥4.7bnat 2024-12-31StandaloneCash and cash equivalents
Cash & equivalents¥5.6bnat 2023-12-31vStandaloneCash and cash equivalents
Cash & equivalents¥4.5bnat 2022-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥4.1bnat 2021-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥752m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥888m2024-01-01 → 2024-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥873m2023-01-01 → 2023-12-31vStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥107m2022-01-01 → 2022-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥777m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥378,0002025-01-01 → 2025-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥557,0002024-01-01 → 2024-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥5m2023-01-01 → 2023-12-31vStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥4m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow−¥20,0002025-01-01 → 2025-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥3m2024-01-01 → 2024-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.9bn2023-01-01 → 2023-12-31vStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥488m2022-01-01 → 2022-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥2.4bn2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-18.332025-01-01 → 2025-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-22.282024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-27.252023-01-01 → 2023-12-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-9.872022-01-01 → 2022-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-20.752021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥90.65at 2025-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥108.97at 2024-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥131.26at 2023-12-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥108.48at 2022-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥107.3at 2021-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio97.8%at 2025-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio98.3%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio98.3%at 2023-12-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio92.5%at 2022-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio97.9%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued43,301,765at 2025-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued43,301,765at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued43,276,765at 2023-12-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued39,579,865at 2022-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued38,958,665at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees23at 2025-12-31StandaloneNumber of employees
Employees25at 2024-12-31StandaloneNumber of employees
Employees28at 2023-12-31vStandaloneNumber of employees
Employees19at 2022-12-31dStandaloneNumber of employees
Employees14at 2021-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

All source rows · 670
ItemContextValueUnit
Patent related expenses sgaPrior1YearDuration_NonConsolidatedMember68580000JPY
Patent related expenses sgaCurrentYearDuration_NonConsolidatedMember52697000JPY
Salaries and allowances sgaPrior1YearDuration_NonConsolidatedMember113425000JPY
Salaries and allowances sgaCurrentYearDuration_NonConsolidatedMember84279000JPY
Compensations sgaPrior1YearDuration_NonConsolidatedMember57309000JPY
Compensations sgaCurrentYearDuration_NonConsolidatedMember43863000JPY
Taxes and dues sgaPrior1YearDuration_NonConsolidatedMember42671000JPY
Taxes and dues sgaCurrentYearDuration_NonConsolidatedMember54961000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2026-03-23
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第11期（自　2025年１月１日　至　2025年12月31日）
Company name cover pageFilingDateInstant
Original text (Japanese)ノイルイミューン・バイオテック株式会社
Company name in english cover pageFilingDateInstantNoile-Immune Biotech Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　玉田　耕治
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区芝大門二丁目12番10号
Telephone number address of registered headquarter cover pageFilingDateInstant03-5843-7819
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)取締役管理部長　永井　寛子
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区芝大門二丁目12番10号
Telephone number nearest place of contact cover pageFilingDateInstant03-5843-7819
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)取締役管理部長　永井　寛子
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE38453
Fund codeFilingDateInstant－
Security codeFilingDateInstant48930
Filer name in japaneseFilingDateInstant
Original text (Japanese)ノイルイミューン・バイオテック株式会社
Filer name in englishFilingDateInstantNoile-Immune Biotech Inc.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第三号様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstantfalse
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstant－
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstantCTE
Current fiscal year start dateFilingDateInstant2025-01-01
Current period end dateFilingDateInstant2025-12-31
Type of current periodFilingDateInstantFY
Current fiscal year end dateFilingDateInstant2025-12-31
Previous fiscal year start dateFilingDateInstant2024-01-01
Comparative period end dateFilingDateInstant2024-12-31
Previous fiscal year end dateFilingDateInstant2024-12-31
Next fiscal year start dateFilingDateInstant－
End date of quarterly or semi annual period of next fiscal yearFilingDateInstant－
Amendment flagFilingDateInstantfalse
Identification of document subject to amendmentFilingDateInstant－
Report amendment flagFilingDateInstantfalse
Xbrl amendment flagFilingDateInstantfalse
Business results of reporting company (text)FilingDateInstantText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 11 of 11 passed
balance sheet identitynon_consolidated 2024-12-31pass
balance sheet identitynon_consolidated 2025-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · net assetsnon_consolidated 2025-12-31pass
statement vs summary · operating cash flownon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · operating cash flownon_consolidated 2025-01-01/2025-12-31pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass
statement vs summary · total assetsnon_consolidated 2025-12-31pass